Literature DB >> 10081641

Role of P-selectin expression in hepatic ischemia and reperfusion injury.

I Singh1, G B Zibari, M F Brown, D N Granger, M Eppihimer, H Zizzi, L Cruz, K Meyer, E Gonzales, J C McDonald.   

Abstract

BACKGROUND: Researchers have shown that reperfusion of ischemic tissues initiates a complex series of reactions that paradoxically injure tissues. Although several mechanisms have been proposed to explain the pathobiology of ischemic/reperfusion (I/R) injury, much attention has focused on adhesion molecules. Our research is intended to show the kinetics of P-selectin in the liver in response to I/R injury.
METHODS: Left-lobar hepatic ischemia was induced for 30 min in 35 C57BL-6 mice and 20 P-selectin-deficient (K-O) mice. P-selectin expression was measured in these mice at 20 min, 2, 5, 12 and 24 h reperfusion times, as well as in control and sham animals. The animals were injected with radio-labeled P-selectin monoclonal antibody and the organs were harvested for counts/g tissue, expressed as the percentage injected dose. Serum liver enzymes were measured and pathological sections of ischemic and control livers were performed. The unpaired t-test was used for statistical analysis.
RESULTS: P-selectin expression showed two peaks in this animal model. The first peak was at 20 min and the second peak at 5 h of reperfusion (p < 0.001). We documented an 8-fold increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT) and lactate dehydrogenase (LDH) levels 10 h following I/R injury. Pathological specimens showed periportal necrosis consistent with an ischemic event. P-selectin K-O mice showed no up-regulation as a separate control group, and the liver enzymes were significantly lower than the wild-type mice at 10 h (p < 0.001).
CONCLUSION: P-selectin has a bimodal expression following hepatic I/R injury. The first peak is attributed to the Weibel-Palade bodies and the second to new translational P-selectin. We noted no difference in the up-regulation of P-selectin in the ischemic and non-ischemic liver lobes in the same animal.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10081641     DOI: 10.1034/j.1399-0012.1999.130103.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  7 in total

1.  Effect of N-desulfated heparin on hepatic/renal ischemia reperfusion injury in rats.

Authors:  Tong Zhou; Jin-Lian Chen; Wei Song; Feng Wang; Ming-Jun Zhang; Pei-Hua Ni; Jian-Guo Geng
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

Review 2.  CXC chemokines play a critical role in liver injury, recovery, and regeneration.

Authors:  Callisia N Clarke; Satoshi Kuboki; Amit Tevar; Alex B Lentsch; Michael Edwards
Journal:  Am J Surg       Date:  2009-09       Impact factor: 2.565

3.  Molecular requirements for sorting of the chemokine interleukin-8/CXCL8 to endothelial Weibel-Palade bodies.

Authors:  Johanna Hol; Axel M Küchler; Finn-Eirik Johansen; Bjørn Dalhus; Guttorm Haraldsen; Inger Oynebråten
Journal:  J Biol Chem       Date:  2009-07-03       Impact factor: 5.157

Review 4.  Molecular mechanisms of liver ischemia reperfusion injury: insights from transgenic knockout models.

Authors:  Gourab Datta; Barry J Fuller; Brian R Davidson
Journal:  World J Gastroenterol       Date:  2013-03-21       Impact factor: 5.742

Review 5.  Hepatic Ischemia/Reperfusion: Mechanisms of Tissue Injury, Repair, and Regeneration.

Authors:  Takanori Konishi; Alex B Lentsch
Journal:  Gene Expr       Date:  2017-09-11

6.  Platelet aggregation but not activation and degranulation during the acute post-ischemic reperfusion phase in livers with no underlying disease.

Authors:  Rowan F van Golen; Katarzyna M Stevens; Pina Colarusso; Hartmut Jaeschke; Michal Heger
Journal:  J Clin Transl Res       Date:  2015-09-13

Review 7.  Regulatory mechanisms of injury and repair after hepatic ischemia/reperfusion.

Authors:  Alex B Lentsch
Journal:  Scientifica (Cairo)       Date:  2012-09-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.